A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC).

Abstract

OBJECTIVES:

The effectiveness of cisplatinum and vinorelbine (PVn) as a salvage regimen in patients with metastatic breast cancer was reported in previous studies. This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients.

METHODS:

Thirty-five patients were enrolled: 22 with metastatic breast carcinoma and 13 with locally advanced breast carcinoma (stage III). A total of 4 cycles of PVn were planned. After the 4th cycle, patients with metastatic breast cancer received vinorelbine biweekly until disease progression or for a total of 12 cycles, whereas those with locally advanced breast cancer who showed complete or partial response underwent curative surgery.

RESULTS:

The overall response rate of our whole population was 74.29%. For the metastatic breast cancer group, the overall response rate was 64%, with a median survival of 19 months (range 2-36). For the locally advanced breast cancer group, the overall response rate was 92.3% with a median time to disease progression of 26 months (range 25-27). Toxicity was acceptable, and no treatment-related mortality was encountered.

CONCLUSIONS:

PVn is effective as first line treatment of advanced breast cancer with overall response rate of 64% in metastatic breast cancer and 92.3% in locally advanced breast cancer, and acceptable toxicity.

• Authors: Ali Shamseddine, Mohammed Khalifeh, Aref Chehal, Teddy Saliba, Yasser Abou Mourad, Ali Taher, Rahif Jalloul, Nizar Bitar, Azzam Dandashi, Jaber Abbas, Fady B Geara
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 28 Issue 4 Pg. 393-8 (Aug 2005) ISSN: 1537-453X [Electronic] United States
• PMID: 16062082 (Publication Type: Clinical Trial, Phase II, Journal Article)

Chemical References

• Vinblastine
• Cisplatin
• Vinorelbine

Topics

• Adenocarcinoma (drug therapy, mortality, pathology, secondary)
• Adult
• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Bone Neoplasms (secondary)
• Breast Neoplasms (drug therapy, mortality, pathology)
• Carcinoma, Ductal (drug therapy, mortality, pathology, secondary)
• Carcinoma, Lobular (drug therapy, mortality, pathology, secondary)
• Cisplatin (administration & dosage)
• Female
• Follow-Up Studies
• Humans
• Liver Neoplasms (secondary)
• Lung Neoplasms (secondary)
• Lymphatic Metastasis
• Middle Aged
• Neoplasm Staging
• Pilot Projects
• Skin Neoplasms (secondary)
• Survival Rate
• Treatment Outcome
• Vinblastine (administration & dosage, analogs & derivatives)
• Vinorelbine